Mizuho Securities Starts Eloxx Pharma (ELOX) at Buy

Mizuho Securities analyst Defei Yang initiates coverage on Eloxx Pharma (NASDAQ: ELOX) with a Buy rating and a price target of $3.10.

The analyst comments "Eloxx Pharmaceuticals is developing novel therapies for nonsense mutations, which are present in ~10% of patients across multiple rare disease settings. Following in the footsteps of Vertex Pharma (not covered), the company's lead program; ELX-02 is in cystic fibrosis patients with nonsense mutations, where the standard of care is currently limited. Clinical data from an ongoing Phase II study is expected in 2H21 and is likely to be a major catalyst for the company. We highlight the bar for success in this report, along with important pre-clinical data from ELX-02 in highly relevant models of CF."

For an analyst ratings summary and ratings history on Eloxx Pharma click here. For more ratings news on Eloxx Pharma click here.

Shares of Eloxx Pharma closed at $1.99 yesterday.

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities
• JPMorgan Upgrades Hyundai Marine and Fire Insurance (001450:KS) to Neutral